SCHEMBL3856784

SCHEMBL3856784

Cc1ccc(C2(O)CCN(C(=O)OC(C)(C)C)CC2)cc1C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.45
OPRL1 P41146 7/20 0.43
OPRM1 P35372 7/20 0.43
OPRD1 P41143 3/20 0.43
SYK P43405 1/20 0.43
OPRK1 P41145 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DRD2 P14416 1/20 0.41
RORC P51449 3/20 0.41
PDK2 Q15119 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
EPHX2 P34913 1/20 0.40
SCN1A P35498 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN3A Q9NY46 1/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273617 0.88 OPRM1 (0.56) OPRL1OPRM1OPRD1OPRK1DRD2
SCHEMBL3386008 0.88 TACR1 (0.45) TACR1OPRL1OPRM1OPRD1SYK
SCHEMBL3851628 0.84 OPRM1 (0.45) OPRL1OPRM1OPRD1OPRK1MEN1
SCHEMBL6586224 0.84 TACR1 (0.48) TACR1OPRL1OPRM1OPRD1OPRK1
SCHEMBL6795066 0.82 MAPT (0.55) TACR1OPRL1OPRM1OPRD1SYK
SCHEMBL6584117 0.81 LMNA (0.46) TACR1MEN1KMT2ADRD2RORC
SCHEMBL31753726 0.81 LMNA (0.46) TACR1MEN1KMT2ADRD2RORC
SCHEMBL2352484 0.81 RORC (0.46) TACR1MEN1KMT2ADRD2RORC
SCHEMBL29532756 0.81 RORC (0.46) TACR1MEN1KMT2ADRD2RORC
SCHEMBL13660794 0.80 TACR1 (0.56) TACR1OPRL1OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765779-B1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2009-11-18 EP disclosed
US-7579474-B2 Substituted piperidines as modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH AB, SVERIGE (DK) 2009-08-25 US disclosed
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2007-11-22 US disclosed
EP-1765779-A1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2007-03-28 EP disclosed
WO-2005121092-A1 NEW SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270467-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION DRD2, PRLHR, DRD3 TACR1 61/4885OPRL1 9/4885OPRM1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.